Cargando…

Hypoglycemic Syndrome in a Patient with Proinsulin-Only Secreting Pancreatic Adenoma (Proinsulinoma)

We describe an unusual case of hypoglycemic syndrome in a 69-year old woman with a proinsulin-only secreting pancreatic endocrine adenoma. The clinical history was highly suggestive of an organic hypoglycemia, with normal or relatively low insulin concentrations and elevated proinsulin levels. Magne...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fadini, Gian Paolo, Maran, Alberto, Valerio, Anna, Meduri, Francesco, Pelizzo, Mariarosa, Miotto, Diego, Lanza, Cristiano, Altavilla, Giuseppe, Avogaro, Angelo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2011
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3135210/ https://www.ncbi.nlm.nih.gov/pubmed/21765847 http://dx.doi.org/10.1155/2011/930904

Ejemplares similares

SAT-LB314 Not That Sweet Honeymoon: A Case of Proinsulinoma
por: Maldonado, Francisco Javier Lopez, et al.
Publicado: (2020)

Intraoperative selective arterial calcium injection test to confirm complete resection of a proinsulinoma
por: Sakamoto, Akimasa, et al.
Publicado: (2022)

It Is All in the Blood: The Multifaceted Contribution of Circulating Progenitor Cells in Diabetic Complications
por: Fadini, Gian Paolo, et al.
Publicado: (2012)

How to interpret the role of SDF-1α on diabetic complications during therapy with DPP-4 inhibitors
por: Fadini, Gian Paolo, et al.
Publicado: (2018)

SAT148 A Rare Case Of Proinsulinoma In A Patient With Type 2 Diabetes Mellitus
por: Tirthani, Ekta, et al.
Publicado: (2023)

Glucagon-like peptide-1 receptor agonists are not associated with retinal adverse events in the FDA Adverse Event Reporting System
por: Fadini, Gian Paolo, et al.
Publicado: (2018)

Pharmacovigilance Evaluation of the Association Between DPP-4 Inhibitors and Heart Failure: Stimulated Reporting and Moderation by Drug Interactions
por: Fadini, Gian Paolo, et al.
Publicado: (2018)

Managing diabetes in diabetic patients with COVID: where do we start from?
por: Avogaro, Angelo, et al.
Publicado: (2021)

Long-Acting Injectable GLP-1 Receptor Agonists for the Treatment of Adults with Type 2 Diabetes: Perspectives from Clinical Practice
por: Morieri, Mario Luca, et al.
Publicado: (2020)

Extraglycemic Effects of SGLT2 Inhibitors: A Review of the Evidence
por: Bonora, Benedetta Maria, et al.
Publicado: (2020)

Cholesterol lowering therapies and achievement of targets for primary and secondary cardiovascular prevention in type 2 diabetes: unmet needs in a large population of outpatients at specialist clinics
por: Morieri, Mario Luca, et al.
Publicado: (2020)

Response to Chia Siang Kow and colleagues
por: Avogaro, Angelo, et al.
Publicado: (2022)

Proinsulin Secretion Is a Persistent Feature of Type 1 Diabetes
por: Sims, Emily K., et al.
Publicado: (2019)

Distinct secretion pattern of serum proinsulin in different types of diabetes
por: Tong, Yue, et al.
Publicado: (2020)

Gastric bypass alters the dynamics and metabolic effects of insulin and proinsulin secretion
por: Johansson, H-E., et al.
Publicado: (2007)

SGLT-2 inhibitors and atrial fibrillation in the Food and Drug Administration adverse event reporting system
por: Bonora, Benedetta Maria, et al.
Publicado: (2021)

Challenges and opportunities in real‐world evidence on the renal effects of sodium‐glucose cotransporter‐2 inhibitors
por: Fadini, Gian Paolo, et al.
Publicado: (2021)

Simvastatin Rapidly and Reversibly Inhibits Insulin Secretion in Intact Single-Islet Cultures
por: Scattolini, Valentina, et al.
Publicado: (2016)

Erratum to: Simvastatin Rapidly and Reversibly Inhibits Insulin Secretion in Intact Single-Islet Cultures
por: Scattolini, Valentina, et al.
Publicado: (2016)

The Endothelium Abridges Insulin Resistance to Premature Aging
por: Avogaro, Angelo, et al.
Publicado: (2013)

Glycemic control after switching to faster aspart in adults with type 1 diabetes
por: Fadini, G. P., et al.
Publicado: (2022)

Amelioration of Glucose Control Mobilizes Circulating Pericyte Progenitor Cells in Type 2 Diabetic Patients with Microangiopathy
por: Fadini, Gian Paolo, et al.
Publicado: (2012)

Endothelial Dysfunction in Diabetes: The role of reparatory mechanisms
por: Avogaro, Angelo, et al.
Publicado: (2011)

Continued efforts to translate diabetes cardiovascular outcome trials into clinical practice
por: Avogaro, Angelo, et al.
Publicado: (2016)

Effects of the SGLT2 inhibitor dapagliflozin on cardiac function evaluated by impedance cardiography in patients with type 2 diabetes. Secondary analysis of a randomized placebo-controlled trial
por: Bonora, Benedetta Maria, et al.
Publicado: (2019)

Glycaemic Control Among People with Type 1 Diabetes During Lockdown for the SARS-CoV-2 Outbreak in Italy
por: Bonora, Benedetta Maria, et al.
Publicado: (2020)

Pharmacovigilance assessment of the association between Fournier’s gangrene and other severe genital adverse events with SGLT-2 inhibitors
por: Fadini, Gian Paolo, et al.
Publicado: (2019)

Time-resolved trajectory of glucose lowering medications and cardiovascular outcomes in type 2 diabetes: a recurrent neural network analysis
por: Longato, Enrico, et al.
Publicado: (2022)

Proinsulin and age in general population
por: Ateia, S, et al.
Publicado: (2013)

Dipeptidyl-peptidase 4 Inhibition: Linking Metabolic Control to Cardiovascular Protection
por: Avogaro, Angelo, et al.
Publicado: (2014)

Sexual Dimorphism in Cellular and Molecular Features in Human ACTH-Secreting Pituitary Adenomas
por: Pecori Giraldi, Francesca, et al.
Publicado: (2020)

Associations of age with serum insulin, proinsulin and the proinsulin-to-insulin ratio: a cross-sectional study
por: Bryhni, Bente, et al.
Publicado: (2010)

The dipeptidyl peptidase-4 inhibitor Saxagliptin improves function of circulating pro-angiogenic cells from type 2 diabetic patients
por: Poncina, Nicol, et al.
Publicado: (2014)

Effectiveness of adding alarms to flash glucose monitoring in adults with type 1 diabetes under routine care
por: Boscari, Federico, et al.
Publicado: (2022)

Immunoradiometric assay of human proinsulin and partially processed proinsulin with use of monoclonal antibody and streptavidin-biotin labeling.
por: Kim, J. Q., et al.
Publicado: (1989)

SUN-LB059 A Rare Case Of Hypoglycemia Secondary To Proinsulin-Intermediate Secreting Tumor
por: Zainal, Abir, et al.
Publicado: (2019)

DPP-4 inhibition has no acute effect on BNP and its N-terminal pro-hormone measured by commercial immune-assays. A randomized cross-over trial in patients with type 2 diabetes
por: Fadini, Gian Paolo, et al.
Publicado: (2017)

Better cardiovascular outcomes of type 2 diabetic patients treated with GLP-1 receptor agonists versus DPP-4 inhibitors in clinical practice
por: Longato, Enrico, et al.
Publicado: (2020)

Cardiovascular outcomes of type 2 diabetic patients treated with SGLT-2 inhibitors versus GLP-1 receptor agonists in real-life
por: Longato, Enrico, et al.
Publicado: (2020)

Cardiovascular outcomes after initiating GLP-1 receptor agonist or basal insulin for the routine treatment of type 2 diabetes: a region-wide retrospective study
por: Longato, Enrico, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_d1ggpldi05q1ncsvlomvdogefv